A new peer-reviewed study in JAACAP, co-authored by Valisure scientists, reveals significant quality concerns in generic methylphenidate products used to treat ADHD.

Key findings include:

• Nearly half of the extended-release generics tested had dissolution profiles that differed significantly from the brand-name drug.
• A probable human carcinogen, N-nitroso-methylphenidate, was found above regulatory limits in 7 of 15 immediate-release generics.
• Products with elevated carcinogen levels were priced similarly to safer alternatives.

The study underscores an urgent need for greater transparency in drug quality—especially when price doesn’t correlate with safety.

Read the full Bloomberg coverage:
Why Your Generic Ritalin Might Not Work →

‍

A new peer-reviewed study in JAACAP, co-authored by Valisure scientists, reveals significant quality concerns in generic methylphenidate products used to treat ADHD.

Key findings include:

• Nearly half of the extended-release generics tested had dissolution profiles that differed significantly from the brand-name drug.
• A probable human carcinogen, N-nitroso-methylphenidate, was found above regulatory limits in 7 of 15 immediate-release generics.
• Products with elevated carcinogen levels were priced similarly to safer alternatives.

The study underscores an urgent need for greater transparency in drug quality—especially when price doesn’t correlate with safety.

Read the full Bloomberg coverage:
Why Your Generic Ritalin Might Not Work →

‍